Alimera Sciences To Hold Conference Call To Discuss Results From The Final Readout Of The FAME(TM) Study Of ILUVIEN(R)
ATLANTA, Jan. 27, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release data from the final readout of the FAME Study after the market close on Thursday, February 3, 2011. The FAME Study consists of two 36-month Phase 3 pivotal clinical trials to assess the safety and efficacy of ILUVIEN® in the treatment of diabetic macular edema (DME).
Alimera will host a conference call and slide show presentation at 4:30 PM ET on February 3, 2011 to discuss the results. The conference call will be hosted by Dan Myers, President and Chief Executive Officer, Ken Green, Chief Scientific Officer and Rick Eiswirth, Chief Operating Officer and Chief Financial Officer.
To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or (253) 237-1165 (international). A live webcast and slide presentation will be available on the Investor Relations section of the corporate website at http://www.alimerasciences.com .A replay of the conference call will be available beginning February 3, 2011 at 7:30 PM ET and ending on February 10, 2011 by dialing (800) 642-1687 (U.S. and Canada) or (706) 645-9291 (international), Conference ID Number: 40417927. About Alimera Sciences, Inc. Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, ILUVIEN®, is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN® is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. A New Drug Application for ILUVIEN® is currently under review by the US Food and Drug Administration.
CONTACT: ICR, LLC for Alimera Sciences John Mills 310-954-1105 John.Mills@icrinc.com
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV